DIA selects Basel to host 30th EuroMeeting
The Drug Information Association (DIA) has chosen Basel in Switzerland as the location for the 30th anniversary of its EuroMeeting in 2018. The event will take place from 17 to 19 April.
The congress will focus on increased collaboration between the regulatory and the health technology assessment (HTA) / payer environment, and to reflect this area of increasing importance, a new steering committee structure, according to DIA.
The central themes for the EuroMeeting will include:
- Can regulators and HTA bodies create synergies for patient access?
- What are necessary steps towards outcome-driven health systems?
- Medicines of the future: what will innovation need and bring?
- How can better outcomes be enabled by big data?
- What is the future of pharmacovigilance?
- What can stakeholders expect from clinical trial (development), transparency and medical information?
- A new era for medical devices and diagnostics. How is the impact?
- Drug development and regulatory approval - reference points around the globe or globalization?
- How can we enable clinical research in Europe further?
- Can new health economic models increase access to innovation and attractiveness for bioventures and investors?
The co-chairs for the 2018 EuroMeeting are Luca Pani, from the European Medicines Agency in London, and Michelle Rohrer, global head of product development regulatory & policy at Roche in Basel.
The deadline for submission of abstracts is 26 June 2017.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
